Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 – 3 mg/24 h for up to 5 years

Bibliography

• Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010;6:337-46
   PubMed Web of Science ®Google Scholar
• International Restless Legs Syndrome Study Group. Revised IRLSSG diagnostic criteria for RLS. Available from: http://irlssg.org/diagnostic-criteria/ [Last accessed 28 November, 2012]
   Google Scholar
• Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000;1:11-19
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Hening WA, Montagna P, Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-302
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Stillman P, Benes H, Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol 2011;11:28
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012;19(11):1385-96
   Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009;379:73-86
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Braun M, Andreas JO, Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34:966-78
   PubMed Web of Science ®Google Scholar
• Neupro (rotigotine transdermal patch). European summary of product characteristics. UCB Pharma, Co; Clare, Ireland: 2012
   Google Scholar
• Neupro (rotigotine transdermal system). US prescribing information. UCB Pharma; Smyrna, GA: 2012
   Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-39
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Poewe W, Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
   PubMed Web of Science ®Google Scholar
• Hening WA, Allen RP, Ondo WG, Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675-83
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-56
   PubMed Web of Science ®Google Scholar
• Oertel W, Trenkwalder C, Benes H, Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10:710-20
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti D, Hening WA, Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. 028 CGI. Clinical Global Impressions. ECDEU assessment manual for psychopharmacology. U.S. Department of Health, Education, and Welfare; Rockville, MD; 1976. p. 217-22
   Google Scholar
• Garcia-Borreguero D, Allen RP, Kohnen R, Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-30
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010;14:339-46
   PubMed Web of Science ®Google Scholar
• Walters AS, LeBrocq C, Dhar A, Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-32
   PubMed Web of Science ®Google Scholar
• Kohnen R, Oertel WH, Stiasny-Kolster K, Severity rating of restless legs syndrome: validation of the RLS-6 scales. Sleep 2004;27:304
   Google Scholar
• Kohnen R, Benes H, Heinrich CR, Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire. Mov Disord 2002;17:S232-S
   Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, Rotigotinetransdermal patch in early Parkinson's disease: a randomized, double-blind, controlled studyversus placebo and ropinirole. Mov Disord 2007;22:2398-404
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, Randomized, blind,controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-6
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, Efficacy of pramipexole and transdermal rotigotine inadvanced Parkinson's disease: a double-blind, double -dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotinetransdermal system: PREFER Study. Neurology 2007;68:1262-7
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Poewe W, Efficacy of rotigotine for treatment of moderate-to-severe RLS: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
   PubMed Web of Science ®Google Scholar